Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 6.1% – Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded up 6.1% during trading on Monday . The company traded as high as $52.49 and last traded at $52.5730. 509,699 shares traded hands during trading, a decline of 35% from the average session volume of 788,567 shares. The stock had previously closed at $49.56.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. HC Wainwright raised their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Truist Financial lifted their target price on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Jefferies Financial Group boosted their price target on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Finally, Wedbush raised their price objective on Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.63.

Dianthus Therapeutics Price Performance

The business’s fifty day simple moving average is $45.59 and its 200 day simple moving average is $38.25. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -15.14 and a beta of 1.59.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 16.56% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of the company. Parkside Financial Bank & Trust increased its position in Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 540 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $40,000. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the second quarter valued at $27,000. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth $64,000. Finally, Royal Bank of Canada raised its holdings in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.